>>Off-hand it looks to me like you're looking at old data.<<
Well ... yeah. I was comparing P2 Pfizer data to P2 Incyte data, rather than comparing P3 to P2.
But thanks for the P3 to P2 comparison. Pfizer's drug minus placebo ACR response rates are still higher for all of ACR20, ACR50 and ACR70, although I agree that only ACR20 looks like it might reach statistical significance.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.